Anzeige
Mehr »
Login
Freitag, 30.10.2020 Börsentäglich über 12.000 News von 650 internationalen Medien
Ist es jetzt 5 vor 12!? Kommt am Wochenende der Game Changer?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLU2 ISIN: SE0009414576 Ticker-Symbol: OND 
Frankfurt
30.10.20
16:15 Uhr
14,770 Euro
+0,350
+2,43 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOPEPTIDES AB Chart 1 Jahr
5-Tage-Chart
ONCOPEPTIDES AB 5-Tage-Chart
RealtimeGeldBriefZeit
15,00015,25017:51

Aktuelle News zur ONCOPEPTIDES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.10.Nomination committee in Oncopeptides established288 STOCKHOLM, Oct. 21, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the composition of the Nomination Committee for the Annual General Meeting 2021...
► Artikel lesen
ONCOPEPTIDES Aktie jetzt für 0€ handeln
21.10.ONCOPEPTIDES AB: Nomination committee in Oncopeptides established2
19.10.Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform131STOCKHOLM, Oct. 19, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the...
► Artikel lesen
19.10.ONCOPEPTIDES AB: Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform1
14.10.Oncopeptides signs € 40 million loan agreement with the EIB242STOCKHOLM, Oct. 14, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Investment Bank...
► Artikel lesen
14.10.ONCOPEPTIDES AB: Oncopeptides signs € 40 million loan agreement with the EIB2
12.10.With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA202STOCKHOLM, Oct. 12, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has informed the European Medicines Agency, EMA, about its intention...
► Artikel lesen
12.10.ONCOPEPTIDES AB: With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA2
01.10.Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma232STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is...
► Artikel lesen
01.10.ONCOPEPTIDES AB: Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma2
08.09.ONCOPEPTIDES AB: Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit4
04.09.Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included299STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the last patient has been successfully enrolled in the pivotal phase 3 study...
► Artikel lesen
04.09.ONCOPEPTIDES AB: Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included-
29.08.ONCOPEPTIDES AB: FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma1
26.08.Oncopeptides AB: Interim Report Q2 2020258STOCKHOLM, Aug. 26, 2020 /PRNewswire/ -- Summary Financial overview April 1 - June 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 401.0...
► Artikel lesen
07.08.Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study296STOCKHOLM, Aug. 7, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the first patient has been enrolled in the Immunoglobulin Light Chain (AL) amyloidosis...
► Artikel lesen
07.08.ONCOPEPTIDES AB: Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study-
04.08.Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma328STOCKHOLM, Aug. 4, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study, which...
► Artikel lesen
04.08.ONCOPEPTIDES AB: Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma1
31.07.Number of shares and votes in Oncopeptides354STOCKHOLM, July 31, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being...
► Artikel lesen
Seite:  Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1